These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Detection of disease-causing CFTR variants in state newborn screening programs. McGarry ME; Ren CL; Wu R; Farrell PM; McColley SA Pediatr Pulmonol; 2023 Feb; 58(2):465-474. PubMed ID: 36237137 [TBL] [Abstract][Full Text] [Related]
9. Genetic counseling access and service delivery in New York State is variable for parents of infants with complex CFTR genotypes conferring uncertain phenotypes. Kay DM; Sadeghi H; Kier C; Berdella M; DeCelie-Germana JK; Soultan ZN; Goetz DM; Caggana M; Fortner CN; Giusti R; Kaslovsky R; Stevens C; Voter K; Welter JJ; ; Langfelder-Schwind E Pediatr Pulmonol; 2024 Jul; 59(7):1952-1961. PubMed ID: 38695616 [TBL] [Abstract][Full Text] [Related]
10. Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS/CFSPID to CF reclassification. Salinas DB; Ginsburg DK; Wee CP; Saeed MM; Brewington JJ Pediatr Pulmonol; 2023 Apr; 58(4):1074-1084. PubMed ID: 36582049 [TBL] [Abstract][Full Text] [Related]
11. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Terlizzi V; Farrell PM Curr Probl Pediatr Adolesc Health Care; 2024 Jun; 54(6):101637. PubMed ID: 38811287 [TBL] [Abstract][Full Text] [Related]
12. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic challenges in CFTR-related metabolic syndrome: Where the guidelines fall short. Kallam EF; Kasi AS; Barr E; Linnemann RW; Guglani L Paediatr Respir Rev; 2024 Mar; 49():28-33. PubMed ID: 37659865 [TBL] [Abstract][Full Text] [Related]
15. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. ; Borowitz D; Parad RB; Sharp JK; Sabadosa KA; Robinson KA; Rock MJ; Farrell PM; Sontag MK; Rosenfeld M; Davis SD; Marshall BC; Accurso FJ J Pediatr; 2009 Dec; 155(6 Suppl):S106-16. PubMed ID: 19914443 [TBL] [Abstract][Full Text] [Related]